SOPHiA GENETICS (NASDAQ:SOPH) Issues Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) posted its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05), Zacks reports. The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• Q2 revenue rose 27% year over year to $23.3 million, with record platform analysis volume of 115,000, up 22%. U.S. revenue grew 64%, while liquid biopsy revenue increased 80%.
• Customer momentum remained strong, with 24 new customers added, net dollar retention improving to 117%, and annualized revenue churn below 1%. Management said the clinical and biopharma pipelines each exceed $100 million.
• The company announced two AstraZeneca companion diagnostic programs, which management described as sizable, multi-year opportunities expected to contribute primarily from 2027 onward and expand SOPHiA’s biopharma platform.
• SOPHiA raised full-year 2026 revenue guidance to $94 million-$96 million from $92 million-$94 million, while reaffirming its adjusted EBITDA loss target of $29 million-$32 million and expectations to reach positive adjusted EBITDA in the second half of 2027.
• Adjusted gross margin declined to 72.1% from 74.4% a year ago, pressured by lower-margin early-stage biopharma projects, customer implementation services, and higher cloud and AI computing costs. The company also reported $12.9 million of quarterly cash burn and completed a $57.5 million equity offering, which may create shareholder dilution.

SOPHiA GENETICS Trading Down 1.7%

SOPH stock traded down $0.11 during midday trading on Thursday, hitting $6.19. The stock had a trading volume of 63,832 shares, compared to its average volume of 212,926. The company’s 50-day moving average price is $5.54 and its 200 day moving average price is $5.12. SOPHiA GENETICS has a 12-month low of $2.96 and a 12-month high of $7.21. The firm has a market cap of $519.28 million, a PE ratio of -5.31 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

Insider Transactions at SOPHiA GENETICS

In other news, Chairman Jurgi Camblong sold 20,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total value of $138,400.00. Following the transaction, the chairman owned 3,472,822 shares of the company’s stock, valued at approximately $24,031,928.24. This trade represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $6.92, for a total value of $69,200.00. Following the transaction, the insider directly owned 600,887 shares in the company, valued at $4,158,138.04. This trade represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 256,092 shares of company stock valued at $1,492,420. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at about $54,000. XTX Topco Ltd acquired a new stake in SOPHiA GENETICS in the fourth quarter worth about $55,000. Susquehanna International Group LLP acquired a new stake in SOPHiA GENETICS in the third quarter worth about $88,000. Finally, Polen Capital Management LLC bought a new position in SOPHiA GENETICS in the 4th quarter valued at about $102,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, implying 22%–24% year-over-year growth and slightly exceeding consensus expectations. Management also continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook article
• Positive Sentiment: The company partnered with AstraZeneca on the development, validation and commercialization of two companion diagnostics for precision-oncology therapies. The collaboration could strengthen SOPH’s position in oncology testing and support longer-term growth. AstraZeneca partnership article
• Positive Sentiment: Analyst sentiment improved, with HC Wainwright raising its price target from $12 to $14 and BTIG Research increasing its target from $8 to $9. Both firms maintained Buy ratings, although HC Wainwright lowered its FY2029 EPS estimate to $0.31 from $0.34 before raising its FY2030 estimate to $0.72 from $0.69.
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu sold a combined 35,000 shares for approximately $242,350 under pre-arranged Rule 10b5-1 trading plans. The sales modestly reduced their holdings and therefore provide limited bearish signaling.
• Negative Sentiment: Second-quarter revenue rose 27% year over year to $23.31 million and exceeded expectations, but the company reported an adjusted loss of $0.26 per share versus the expected $0.21 loss. Persistent losses, including a negative net margin, may be driving investor caution despite the stronger revenue outlook. Second-quarter results presentation

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SOPH shares. BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.